- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vertex Pharmaceuticals Inc DRC (VRTX34)
Vertex Pharmaceuticals Inc DRC stock price live, this page displays BVMF VRTX34 stock exchange data. View the VRTX34 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vertex Pharmaceuticals Inc DRC real time stock price chart below.
What Is the Vertex Pharmaceuticals Inc DRC Stock Price Today?
The Vertex Pharmaceuticals Inc DRC stock price today is 83.28.
What Is the Stock Symbol for Vertex Pharmaceuticals Inc DRC?
The stock symbol for Vertex Pharmaceuticals Inc DRC is "VRTX34."
What Stock Exchange Does Vertex Pharmaceuticals Inc DRC Trade On?
Vertex Pharmaceuticals Inc DRC is listed and trades on the B3 stock exchange.
Is Vertex Pharmaceuticals Inc DRC a Good Stock to Buy?
Determining whether Vertex Pharmaceuticals Inc DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRTX34 quote. (ISIN: BRVRTXBDR001)
What Is the Vertex Pharmaceuticals Inc DRC Stock Price Today?
The Vertex Pharmaceuticals Inc DRC stock price today is 83.28.
What Is the Stock Symbol for Vertex Pharmaceuticals Inc DRC?
The stock symbol for Vertex Pharmaceuticals Inc DRC is "VRTX34."
What Stock Exchange Does Vertex Pharmaceuticals Inc DRC Trade On?
Vertex Pharmaceuticals Inc DRC is listed and trades on the B3 stock exchange.
Is Vertex Pharmaceuticals Inc DRC a Good Stock to Buy?
Determining whether Vertex Pharmaceuticals Inc DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRTX34 quote. (ISIN: BRVRTXBDR001)
83.28
-1.59(-1.87%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
82.48
83.28
52 wk Range
62.20
86.31
VRTX34 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
82.4883.28
52 wk Range
62.2086.31
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
VRTX34 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Earnings
Latest Release
Aug 03, 2026
EPS / Forecast
4.31 / --
Revenue / Forecast
3.33B / --
Compare VRTX34 to Peers and Sector
Metrics to compare | VRTX34 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVRTX34PeersSector | |
|---|---|---|---|---|
P/E Ratio | 29.7x | 24.3x | −0.3x | |
PEG Ratio | 1.34 | −1.32 | 0.00 | |
Price/Book | 6.5x | 5.8x | 2.6x | |
Price / LTM Sales | 10.4x | 4.0x | 3.1x | |
Upside (Analyst Target) | - | 0.0% | 49.0% | |
Fair Value Upside | Unlock | 12.7% | 6.3% | Unlock |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Vertex Pharmaceuticals DRC (VRTX34) Stock Price Today?
The Vertex Pharmaceuticals DRC stock price today is 83.28 BRL.
What Stock Exchange Does Vertex Pharmaceuticals DRC Trade On?
Vertex Pharmaceuticals DRC is listed and trades on the B3 Stock Exchange.
What Is the Stock Symbol for Vertex Pharmaceuticals DRC?
The stock symbol for Vertex Pharmaceuticals DRC is "VRTX34."
What Is the Vertex Pharmaceuticals DRC Market Cap?
As of today, Vertex Pharmaceuticals DRC market cap is 679.56B BRL.
What Is Vertex Pharmaceuticals DRC's Earnings Per Share (TTM)?
The Vertex Pharmaceuticals DRC EPS (TTM) is 17.18.
From a Technical Analysis Perspective, Is VRTX34 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Vertex Pharmaceuticals DRC Stock Split?
Vertex Pharmaceuticals DRC has split 1 times.
How Many Employees Does Vertex Pharmaceuticals DRC Have?
Vertex Pharmaceuticals DRC has 6400 employees.
What is the current trading status of Vertex Pharmaceuticals DRC (VRTX34)?
As of Aug 18, 2026, Vertex Pharmaceuticals DRC (VRTX34) is trading at a price of 83.28 BRL, with a previous close of 83.28 BRL. The stock has fluctuated within a day range of 82.48 BRL to 83.28 BRL, while its 52-week range spans from 62.20 BRL to 86.31 BRL.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.